An observational study in Epilepsy, Pediatric Epilepsy and Autonomic Dysfunction, sponsored by Assiut University. Not yet recruiting. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Epilepsy by Assiut University — 8 open to participants now, 8 under way, none of them phase 3. Epilepsy · Assiut University.
Among the 15 studies in Epilepsy by Assiut University, this one is the 10th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2026, is one of 12 observational ones, and was the 14th registered.
1,848 studies on the registry are indexed under Epilepsy; 420 are open to participants now.
Browse Epilepsy studies →8 of the 15 studies in Epilepsy by Assiut University are open now. Recruiting first, the newest first:
Assiut University
Ages 1–18
Assiut University
Assiut University
Ages 3–18
Assiut University
Ages 1–18
Assiut University
Ages 5–18
Of the 283 Epilepsy studies recruiting now, 112 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 140 take children under 18; 55 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 112 across 540 observational studies indexed under Epilepsy.
Median enrollment 98 across the 3 interventional studies, 92 across the 12 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,079 studies on the registry; 2,177 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Epilepsy by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07241754Assiut UniversityPredictors of Drug Resistant Epilepsy Among Pediatric Patients | 2026-12-29 |
| NCT07205211Assiut UniversityPrevalence of ADHD in Children With Epilepsy | 2027-01-01 |
| NCT07343609Assiut UniversityPredictive Value of Seizure Frequency at Onset for Long-Term Seizure Control | 2027-01-10 |
| NCT07834983Assiut UniversityTime-Domain Heart Rate Variability and QT Interval in Children With Epilepsy | 2027-10 |
| NCT07883980Assiut UniversityAntiseizure Medications and CBC in Children With Epilepsy | 2027-10-20 |
Add all 5 to your calendar (.ics) → With an account.
Among the 15 studies in Epilepsy by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Epilepsy is a chronic neurological disorder characterized by recurrent unprovoked seizures, but it can also affect the autonomic nervous system and cardiovascular function. Certain anti-epileptic medications and seizure activity may influence cardiac rhythm, beat-to-beat heart rate variability (HRV), and ventricular repolarization (measured by the QT interval). The primary purpose of this study is to evaluate autonomic tone and cardiac electrical conduction in children with epilepsy receiving anti-epileptic drugs by measuring time-domain HRV and the corrected QT (QTc) interval, comparing patients on monotherapy, patients on polytherapy, and healthy controls.
A total of 60 children aged 1 to 18 years will be enrolled across three groups: 20 children with epilepsy receiving single-drug therapy (monotherapy), 20 children with epilepsy receiving two or more medications (polytherapy), and 20 healthy children serving as controls.
All participants will complete non-invasive assessments during a single visit, including:
The findings aim to detect early autonomic or electrophysiological alterations, aiding in the understanding of cardiac safety in pediatric epilepsy management.
Eligible children aged 1 to 18 years presenting to the Pediatric Neurology Department at Assiut University Children's Hospital, Assiut, Egypt. The population comprises pediatric patients with a confirmed diagnosis of epilepsy according to ILAE criteria maintained on anti-epileptic monotherapy or polytherapy for at least 3 months, alongside age- and sex-matched healthy controls.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children aged 1 to 18 years diagnosed with epilepsy according to International League Against Epilepsy (ILAE) criteria who have been receiving a single anti-epileptic medication for at least 3 months. Participants undergo a standard 12-lead ECG for corrected QT interval (QTc) calculation and a 5-minute short-term resting ECG in the supine position for time-domain heart rate variability (HRV) assessment
Children aged 1 to 18 years diagnosed with epilepsy according to International League Against Epilepsy (ILAE) criteria who have been receiving two or more anti-epileptic medications for at least 3 months. Participants undergo a standard 12-lead ECG for corrected QT interval (QTc) calculation and a 5-minute short-term resting ECG in the supine position for time-domain heart rate variability (HRV) assessment.
Age- and sex-matched healthy children aged 1 to 18 years without a diagnosis of epilepsy, structural heart disease, acute concurrent illness, or chronic systemic disorders. Participants undergo identical evaluation, including a standard 12-lead ECG for QTc calculation and a 5-minute short-term resting ECG in the supine position for time-domain HRV assessment.
Corrected QT Interval (QTc)
Corrected QT interval (reported in milliseconds) measured from a standard 12-lead ECG recorded at standard velocity and amplitude. The QT interval is measured in lead V5 (or lead II if lead V5 is unsuitable) across three consecutive cardiac cycles and averaged. QTc is calculated using Fridericia's formula: QTc = QT / RR\^(1/3).
Time frame: Baseline
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.